Scientists Discover Simple Amino Acid Cocktail That Boosts mRNA and CRISPR Delivery

A team of scientists at Biohub has found that co-injecting three common amino acids alongside lipid nanoparticles — the same delivery technology behind COVID-19 mRNA vaccines — can increase mRNA delivery to cells up to 20-fold and push CRISPR gene editing efficiency from roughly 25% to nearly 90% in a single dose, according to a study published Wednesday in Science Translational Medicine.

The discovery, led by Daniel Zongjie Wang and Shana O. Kelley, offers a strikingly simple workaround to one of the most persistent obstacles in genetic medicine: lipid nanoparticles, or LNPs, work far better in laboratory dishes than they do inside living organisms.

A Metabolic Bottleneck, Not a Design Flaw

Rather than attempting to engineer a better nanoparticle, the Biohub team investigated why cells in the body are so much worse at absorbing LNPs than cells grown in standard lab conditions. They found that when cells were cultured in a medium mimicking the nutrient-lean environment of human blood plasma, LNP uptake dropped 50% to 80%.

​

Metabolic analysis traced the problem to suppressed amino acid pathways. "The field has spent enormous effort engineering nanoparticles," Wang said. "We found, however, that the cell's own metabolic state is an equally important — and addressable — part of the equation."

​

Through systematic screening, the team identified an optimized supplement of methionine, arginine, and serine that restored and amplified the cellular uptake pathway. The cocktail worked across intramuscular, intratracheal, and intravenous delivery routes and was effective regardless of the specific lipid formulation or mRNA cargo used.

Striking Results in Preclinical Models:

In mice with acetaminophen-induced acute liver failure, LNPs carrying growth hormone mRNA produced only a 33% survival rate when administered alone. With the amino acid supplement, every mouse survived, therapeutic protein levels rose nearly nine-fold, and markers of liver damage dropped to near-healthy levels.

In a separate set of experiments targeting lung tissue with CRISPR-Cas9, a single dose without the supplement achieved editing efficiencies of 20% to 30%. Adding the amino acid cocktail pushed that figure to 85% to 90% — a result that could prove transformative for diseases like cystic fibrosis that demand efficient gene correction in the lungs.